116 related articles for article (PubMed ID: 35190802)
1. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML; Chen SC; Stricker T; Hyman DM; Blauvelt N; Bedard PL; Meric-Bernstam F; Punglia RS; Schrag D; Lepisto EM; Andre F; Smyth L; Dogan S; Yu C; Wathoo C; Levy M; Eli LD; Xu F; Mann G; Lalani AS; Ye F; Micheel CM; Arnedos M
Clin Cancer Res; 2022 May; 28(10):2118-2130. PubMed ID: 35190802
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
Uchida S; Kojima T; Sugino T
Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
[TBL] [Abstract][Full Text] [Related]
4. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
5. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
[TBL] [Abstract][Full Text] [Related]
6. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
7. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
[TBL] [Abstract][Full Text] [Related]
8. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
11. Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Jongen L; Floris G; Boeckx B; Smeets D; Lambrechts D; Vander Borght S; Laenen A; Mann G; Cutler RE; Lalani AS; Neven P; Wildiers H
Breast Cancer Res Treat; 2019 Feb; 174(1):55-63. PubMed ID: 30456437
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
[TBL] [Abstract][Full Text] [Related]
13. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Grote I; Bartels S; Christgen H; Radner M; Gronewold M; Kandt L; Raap M; Lehmann U; Gluz O; Graeser M; Kuemmel S; Nitz U; Harbeck N; Kreipe H; Christgen M
Mod Pathol; 2022 Dec; 35(12):1804-1811. PubMed ID: 35842479
[TBL] [Abstract][Full Text] [Related]
14. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
18. ERBB2 mutation: A promising target in non-squamous cervical cancer.
Xiang L; Jiang W; Ye S; He T; Pei X; Li J; Chan DW; Ngan HYS; Li F; Tao P; Shen X; Zhou X; Wu X; Yang G; Yang H
Gynecol Oncol; 2018 Feb; 148(2):311-316. PubMed ID: 29279289
[TBL] [Abstract][Full Text] [Related]
19. Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
Riedlinger GM; Joshi S; Hirshfield KM; Barnard N; Ganesan S
Breast Cancer Res; 2021 Jan; 23(1):7. PubMed ID: 33441174
[TBL] [Abstract][Full Text] [Related]
20. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
Ding Q; Chen H; Lim B; Damodaran S; Chen W; Tripathy D; Piha-Paul S; Luthra R; Meric-Bernstam F; Sahin AA
Hum Pathol; 2019 Oct; 92():32-38. PubMed ID: 31351155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
